Update on the Boston ISPE’s Response to the COVID-19 Outbreak

Posted by Eric Felz
On March 11, 2020

Dear Colleagues, Today I am providing an important update from the Boston Area Chapter of ISPE Board of Directors regarding the COVID-19 outbreak. As you are aware, the Governor of Massachusetts has declared a state of emergency and many companies across New England are taking measures such as “social distancing” to keep their employees safe […]

Takeda Attacks Coronavirus

Posted by ISPE Boston
On March 11, 2020

Rajeev Venkayya, President of Takeda’s Global Vaccine Business Unit, has announced that Takeda is “initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, which we’re calling TAK-888. SARS-CoV-2 is the virus that causes COVID-19.” He went on to explain that “Hyperimmune globulin is a plasma derived-therapy that has previously been […]

Annual Ski Outing Turns 20!

Posted by Skimeister Jim Grunwald
On March 9, 2020

On March 6th the ISPE Boston Area Chapter Social Committee hosted the 20th Annual Ski/Snowboard Outing. Record attendance of 145 attendees would have made things cozy on the bus, so a second bus was chartered to accommodate the huge response. A special thank you to all of our Sponsors for making this possible (two buses […]

Thermo Fisher to Acquire Qiagen for $10 Billion

Posted by ISPE Boston
On March 5, 2020

Thermo Fisher Scientific will acquire Netherlands-based Qiagen for approximately $11.5 billion, which includes the assumption of approximately $1.4 billion of net debt. Qiagen is a leading provider of life science and molecular diagnostic solutions and employs approximately 5,100 people at 35 locations in more than 25 countries and generated 2019 revenue of $1.53 billion. Its […]

Akrevia Rebrands as Xilio and Announces $100M Series B Financing

Posted by ISPE Boston
On March 5, 2020

Xilio Therapeutics (formerly Akrevia Therapeutics), a local bioteh developing tumor-selective immuno-oncology (IO) therapies for patients with cancer, has announced the closing of a $100.5 million Series B financing. Proceeds from the financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) […]

Biogen and Sangamo Announce Global Collaboration for Alzheimer’s, Parkinson’s

Posted by ISPE Boston
On March 5, 2020

Biogen and California biotech Sangamo Therapeutics have announced a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology […]

Chapter Member Anniversaries: March 2020

Posted by ISPE Boston
On March 5, 2020

Please congratulate the following members celebrating milestone anniversaries in March 2020. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Saboo Aghababayan, MS, MBA, Genzyme Stig Bockman-Pedersen, CCQV Services Ronald C. Case, Superior Controls, Inc. Dr. Charles L. Cooney, PhD, MIT Chemical Engineering Michael B. Cronin, ImmuCell Corporation […]

Welcome New Members February 2020!

Posted by ISPE Boston
On March 5, 2020

We would like to introduce the Members who joined ISPE in February 2020, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

Bicycle Therapeutics in $30M Deal with Genentech

Posted by ISPE Boston
On February 27, 2020

Bicycle Therapeutics has announced a strategic collaboration agreement with Genentech to discover, develop and commercialize novel immuno-oncology therapies. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. By entering into this early discovery collaboration with Genentech, Bicycle will be exploring its technology on a […]

More about Moderna’s Prophylactic Vaccines Modality

Posted by ISPE Boston
On February 27, 2020

Moderna scientists designed the prophylactic vaccines modality to prevent infectious diseases. More than 1,000 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Based on clinical experience across six Phase 1 studies, the Company has designated prophylactic vaccines a core modality and intends to […]

Page 69 of 117«‹67 686970 71 ›»